AstraZeneca to buy lipid drug developer for $443M

Candace Stuart | | Cardiovascular Business | Structural Heart Disease

AstraZeneca will pay up to $443 million to buy a pharmaceutical company that is developing a treatment for dyslipidemia.

AstraZeneca said it is acquiring Omthera, a Princeton, N.J.-based firm that is developing the investigational drug Epanova. The drug has a novel omega-3 free fatty acid composition that AstraZeneca said has been shown to reduce triglyceride levels and improve other key lipid parameters.

Under the terms of the agreement, AstraZeneca will acquire Omthera for about $323 million, with an additional $120 million if specified milestones are met.  

Omthera is expected to file a new drug application (NDA) for Epanova with the FDA in mid-2013 for patients with severe hypertriglyceridemia. London-based AstraZeneca added that it also has numerous plans for the drug, including filing a supplemental NDA for Epanova for patients with mixed dyslipidemia and as a fixed-dose combination with its statin rosuvastatin (Crestor) for mixed dyslipidemia patients at high risk of a cardiovascular event.

The transaction is expected to close in the third quarter of 2013.

Candace Stuart, Contributor

Related Content

CMS proposes Medicare coverage for transcatheter tricuspid valve replacement
Hydra TAVR valve gains key approval as global reach continues to grow
SAVR outperforms TAVR in patients with bicuspid aortic valves
Treating AFib patients with TAVR still linked to elevated risks
Heart surgeons detail world’s first robotic heart procedure of its kind
Years of progress have made TAVR more effective when treating concomitant mitral stenosis

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.